Market capitalization | $11.95b |
Enterprise Value | $12.16b |
P/E (TTM) P/E ratio | 80.13 |
EV/FCF (TTM) EV/FCF | 49.62 |
EV/Sales (TTM) EV/Sales | 10.38 |
P/S ratio (TTM) P/S ratio | 10.20 |
P/B ratio (TTM) P/B ratio | 5.76 |
Dividend yield | 0.42% |
Last dividend (FY24) | $0.32 |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
17 Analysts have issued a Bio-Techne Corporation forecast:
17 Analysts have issued a Bio-Techne Corporation forecast:
Sep '24 |
+/-
%
|
||
Revenue | 1,172 1,172 |
2%
2%
|
|
Gross Profit | 874 874 |
13%
13%
|
|
EBITDA | 345 345 |
11%
11%
|
EBIT (Operating Income) EBIT | 234 234 |
16%
16%
|
Net Profit | 151 151 |
39%
39%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Biotechnology, Protein Platforms, Diagnostics, and Corporate. The Biotechnology segment supplies specialized proteins, such as cytokines and growth factors, immunoassays, antibodies and related reagents, as well as in situ hybridization, media and other cell culture products and reagents to the biotechnology research community. The Protein Platforms segment develops, manufactures, and sells tools to simplify protein analysis. The Diagnostics segment includes blood chemistry and blood gas quality controls, hematology instrument controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market worldwide. The company was founded on 1976 and is headquartered in Minneapolis, MN.
Head office | United States |
CEO | Kim Kelderman |
Employees | 3,100 |
Founded | 1976 |
Website | www.bio-techne.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.